4,426 results on '"Dong, Haidong"'
Search Results
2. Synthesis and evaluation of anti-PD-L1-B11 antibody fragments for PET imaging of PD-L1 in breast cancer and melanoma tumor models
3. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial
4. Solid cancer-directed CAR T cell therapy that attacks both tumor and immunosuppressive cells via targeting PD-L1
5. A digital microfluidic device integrated with electrochemical sensor and 3D matrix for detecting soluble PD-L1
6. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma
7. Single cell profiling at the maternal–fetal interface reveals a deficiency of PD-L1+ non-immune cells in human spontaneous preterm labor
8. Noncanonical TRAIL Signaling Promotes Myeloid-Derived Suppressor Cell Abundance and Tumor Growth in Cholangiocarcinoma
9. Resilient T-cell responses in patients with advanced cancers
10. Effect of design parameters on degree of blending and performance of recycled hot-mix asphalt incorporating fine reclaimed asphalt pavement particles
11. Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity
12. Single cell RNA sequencing unravels mechanisms underlying senescence-like phenotypes of alveolar macrophages
13. Secreted ORF8 induces monocytic pro-inflammatory cytokines through NLRP3 pathways in patients with severe COVID-19
14. Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated With Immune Checkpoint Inhibitors
15. Circulating antigen-primed cytotoxic T-cells in patients with renal tumors treated with surgery
16. Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in Oligometastatic Prostate Cancer and Suppress Antitumor Immunity
17. Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer
18. Advancing CAR T-Cell Therapy: Simultaneously Attack Tumor and Immunosuppressive Cells in the Tumor Microenvironment
19. VALUE OF B7-H3 EXPRESSION AS A PREDICTOR OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN UROTHELIAL CELL CARCINOMA OF BLADDER
20. Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model
21. T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy
22. The Basic Concepts in Cancer Immunology and Immunotherapy
23. Oncology: Emerging Therapeutic Approaches
24. Supplementary Figure from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy
25. Supplementary Data from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy
26. Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups
27. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma
28. Regulation of sister chromatid cohesion by nuclear PD-L1
29. Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma
30. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
31. Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT
32. Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy
33. TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas.
34. Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8 + T cells via ME1 up-regulation
35. TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas
36. 539 Depletion of soluble PD-L1 with engineered NaNot®nanoparticles promotes antitumor immunity
37. 540 A novel antibody that induces PD-L1 degradation results in enhanced tumor responses in a humanized PD-L1 breast carcinoma mouse model compared to Atezolizumab
38. 28 Toward an automated microfluidic platform for monitoring immune response to immunotherapy
39. 477 A novel antibody targeting human monocyte-intrinsic PD-L1 promotes immune stimulatory functions of monocytes for antitumor immunity
40. Synthesis and radiolabeling of diabody fragment of anti-PD-L1-B11 antibody for PET imaging of PD-L1 in a melanoma tumor mouse model
41. 920 ETS-1 regulates the activation of human CD8 T-Cells in response to immune checkpoint inhibitors
42. Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer
43. Immune resilience in response to cancer therapy
44. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome
45. BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts
46. Costimulatory B7-H1 in Renal Cell Carcinoma Patients: Indicator of Tumor Aggressiveness and Potential Therapeutic Target
47. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
48. Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
49. Phase transformation and multiphase reaction properties of complex copper ore system under melting conditions.
50. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.